We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$8.12B
AUM Growth
+$2.18B
Cap. Flow
+$164M
Cap. Flow %
2.02%
Top 10 Hldgs %
63.91%
Holding
78
New
15
Increased
7
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$98.6M
2
BLTE
Belite Bio
BLTE
+$57.4M
3
RNAM
Avidity Biosciences
RNAM
+$55.6M
4
LBRX
LB Pharmaceuticals
LBRX
+$28.2M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$25.4M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$92.5M
2
RXST icon
RxSight
RXST
+$48.1M
3
TRML
Tourmaline Bio
TRML
+$40.6M
4
ELVN icon
Enliven Therapeutics
ELVN
+$17M
5
HNGE
Hinge Health
HNGE
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Financials 0.1%
3 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBNX
76
Beta Bionics
BBNX
$865M
– –
-500,000
Closed -$7.28M
HNGE
77
Hinge Health
HNGE
$7.46B
– –
-300,000
Closed -$15.5M
OMDA
78
Omada Health Inc
OMDA
$1.2B
– –
-400,000
Closed -$7.32M
1 2 3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, RA Capital Management held 78 positions worth $8.12B, up 37% from $5.94B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

RA Capital Management's Q3 2025 filing shows 15 new, 7 increased, 2 reduced and 11 closed positions. Its largest new stake was Nuvalent: 1,246,456 shares worth $108M. The largest sale was Dyne Therapeutics, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q3 2025 buy was Nuvalent: 1,246,456 shares worth $108M.
  • RA Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $55.6M increase.
  • RA Capital Management's biggest Q3 2025 reduction was Avalo Therapeutics, cutting an estimated $2.32M.
  • RA Capital Management fully exited Dyne Therapeutics in Q3 2025, selling an estimated $92.5M.
  • RA Capital Management's ten largest holdings make up 64% of its $8.12B portfolio in Q3 2025.
  • RA Capital Management opened 15 new positions and closed 11 in Q3 2025.
  • RA Capital Management's portfolio value rose 37% quarter-over-quarter to $8.12B.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.